Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Emanuel Petricoin on Genomic Profiling and Targeted Therapy

March 22nd 2013

Emanuel "Chip" Petricoin III, PhD, from George Mason University, discusses the inability of DNA and RNA profiling to predict response to treatment with targeted therapies.

Dr. Cheson on Novel ADCs in Non-Hodgkin Lymphoma

March 20th 2013

Bruce D. Cheson, MD, from Georgetown Lombardi Comprehensive Cancer Center, discusses the prospect of using antibody drug conjugates in non-Hodgkin lymphomas, including follicular lymphoma.

Managing NETs in the Community Setting

March 14th 2013

Treating Neuroendocrine Tumors With Chemotherapy

March 14th 2013

Targeted Therapies in Neuroendocrine Tumors

March 14th 2013

Emerging Treatment Options in Neuroendocrine Tumors

March 14th 2013

Role of Somatostatin Analogs in Neuroendocrine Tumors

March 14th 2013

Surgical Treatment of Neuroendocrine Tumors

March 14th 2013

The Genetics Behind Familial Neuroendocrine Tumors

March 14th 2013

Techniques for Diagnosing Neuroendocrine Tumors

March 14th 2013

Challenges in the Diagnosis of Neuroendocrine Tumors

March 14th 2013

The Role of Biomarkers in Neuroendocrine Tumors

March 14th 2013

Histological Classification of Neuroendocrine Tumors

March 14th 2013

Neuroendocrine Tumors: Introduction and Overview

March 14th 2013

Making Time for Innovation: Myeloma Expert Sets Brisk Pace of Discovery

March 11th 2013

Working in the laboratory and the clinic, Shaji K. Kumar, MD, has made a discovery: that there aren't enough hours in a day.

Dr. Ron Bose on HER2 Gene Mutations in Breast Cancer

March 8th 2013

Ron Bose, MD, PhD, from the Siteman Cancer Center, discusses the prevalence of HER2 gene mutations in patients diagnosed with breast cancer.

EGFR's Evolution: New Insights Refine Role of Mutation in NSCLC

March 1st 2013

Despite all we have learned about the importance of sensitizing EGFR mutations in defining the management of advanced NSCLC, our education regarding the relevance of this molecular target in optimizing clinical outcomes continues.

Notch Holds Promise, but Presents Obstacles as Cancer Target

March 1st 2013

Benjamin W. Purow, MD, a researcher whose focus is on glioblastomas, discusses the Notch pathway and the development of Notch-targeted anticancer agents.

EGFR Mutation Not a Prognostic Factor for NSCLC

February 28th 2013

Although the presence of an EGFR mutation is a predictive marker for response to EGFR tyrosine kinase inhibitor therapy in patients with non-small cell lung cancer, the mutation is not a prognostic factor.

Notch Signaling: Tackling a Complex Pathway With a New Generation of Agents

February 27th 2013

Notch-targeted agents that were initially intended for the treatment of Alzheimer disease are now being examined for their possible anticancer activity.